GPP
VYGR icon

Great Point Partners’s Voyager Therapeutics VYGR Stock Holding History

Great Point Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-626,275
Closed -$2.12M – 37
2025
Q1 		$2.12M Sell
626,275
-200,476
-24% -$936K 1.12% 29
2024
Q4 		$4.69M Sell
826,751
-133,202
-14% -$859K 2.21% 20
2024
Q3 		$5.62M Sell
959,953
-641,574
-40% -$4.66M 1.65% 23
2024
Q2 		$12.7M Buy
+1,601,527
New +$13.4M 2.43% 19
2019
Q1 		– Sell
-365,132
Closed -$3.43M – 51
2018
Q4 		$3.43M Sell
365,132
-1,034,868
-74% -$13.3M 0.43% 33
2018
Q3 		$26.5M Buy
1,400,000
+669,990
+92% +$12.9M 4.13% 10
2018
Q2 		$14.3M Buy
+730,010
New +$14.4M 1.98% 18

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's VYGR Position: Q2 2025 in Review

Great Point Partners sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 626,275 shares — an estimated $2.12M sold.

Great Point Partners first reported a position in VYGR in Q2 2018 and held it in 7 quarters. The position peaked at $26.5M in Q3 2018. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • Great Point Partners reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Great Point Partners sold 626,275 Voyager Therapeutics shares in Q2 2025, an estimated $2.12M.
  • Great Point Partners first reported a position in Voyager Therapeutics in Q2 2018 and held it in 7 quarters.
  • Great Point Partners's Voyager Therapeutics position peaked at $26.5M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on Great Point Partners's 13F filing for Q2 2025, filed 14 Aug 2025.